PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12813134-9 2003 Flavopiridol treatment of docetaxel-treated cells enhances the exit from mitosis with a more rapid decrease in mitotic markers including MPM-2 labeling and cyclin B1/cdc2 kinase activity. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 166-170 11960485-1 2002 Novel 2-benzylidene-benzofuran-3-ones were designed and synthesized to mimic flavopiridol, a well-established inhibitor of cyclin-dependent kinases (CDKs) which is currently undergoing clinical evaluation. alvocidib 77-89 cyclin dependent kinase 1 Homo sapiens 149-153 12054639-1 2002 Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 48-58 12054639-1 2002 Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 60-92 12054639-4 2002 This structural model indicates that the inhibitor strongly binds to the ATP-binding pocket of CDK9 and the structural comparison of the complex CDK2-flavopiridol correlates the structural differences with differences in inhibition of these CDKs by flavopiridol. alvocidib 150-162 cyclin dependent kinase 1 Homo sapiens 241-245 12054639-4 2002 This structural model indicates that the inhibitor strongly binds to the ATP-binding pocket of CDK9 and the structural comparison of the complex CDK2-flavopiridol correlates the structural differences with differences in inhibition of these CDKs by flavopiridol. alvocidib 249-261 cyclin dependent kinase 1 Homo sapiens 241-245 11960485-3 2002 Inhibitors of CDKs 1 and 2 that are more potent and selective than flavopiridol were obtained. alvocidib 67-79 cyclin dependent kinase 1 Homo sapiens 14-26 10363974-1 1999 Analysis of the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen data using the COMPARE algorithm to detect similarities in the pattern of compound action to flavopiridol, a known inhibitor of cyclin-dependent kinases (CDKs), has suggested several possible novel CDK inhibitors. alvocidib 181-193 cyclin dependent kinase 1 Homo sapiens 242-246 11093360-2 2000 Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). alvocidib 15-27 cyclin dependent kinase 1 Homo sapiens 53-68 11464216-1 2001 Flavopiridol (FP), an inhibitor of cyclin dependent kinases 1, 2 and 4, potently induced apoptosis in U937 human monoblastic leukemia cells. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 35-70 11464216-1 2001 Flavopiridol (FP), an inhibitor of cyclin dependent kinases 1, 2 and 4, potently induced apoptosis in U937 human monoblastic leukemia cells. alvocidib 14-16 cyclin dependent kinase 1 Homo sapiens 35-70 11063609-1 2000 Flavopiridol analogues, thio- and oxoflavopiridols which contain a sulfur (16) or oxygen (18) atom linker between a chromone ring and the hydrophobic side chain, are selective cyclin-dependent kinase 1 (CDK1) inhibitors with an IC(50) of 110 and 130 nM. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 176-201 11063609-1 2000 Flavopiridol analogues, thio- and oxoflavopiridols which contain a sulfur (16) or oxygen (18) atom linker between a chromone ring and the hydrophobic side chain, are selective cyclin-dependent kinase 1 (CDK1) inhibitors with an IC(50) of 110 and 130 nM. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 203-207 11063609-7 2000 CDK1 selective thio- and oxoflavopiridol analogues inhibit the colony-forming ability of multiple human tumor cell lines and possess a unique antiproliferative profile in comparison to flavopiridol. alvocidib 28-40 cyclin dependent kinase 1 Homo sapiens 0-4 16127615-4 1999 There is a lot of interest in targeting cyclin-dependent kinases (cdk): flavopiridol (Hoechst AG), a broad-spectrum inhibitor of cdk1, cdk2 and cdk4 is now entering phase II trials. alvocidib 72-84 cyclin dependent kinase 1 Homo sapiens 66-69 16127615-4 1999 There is a lot of interest in targeting cyclin-dependent kinases (cdk): flavopiridol (Hoechst AG), a broad-spectrum inhibitor of cdk1, cdk2 and cdk4 is now entering phase II trials. alvocidib 72-84 cyclin dependent kinase 1 Homo sapiens 129-133 10363974-1 1999 Analysis of the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen data using the COMPARE algorithm to detect similarities in the pattern of compound action to flavopiridol, a known inhibitor of cyclin-dependent kinases (CDKs), has suggested several possible novel CDK inhibitors. alvocidib 181-193 cyclin dependent kinase 1 Homo sapiens 242-245 10500810-6 1999 Olomoucine (OC), flavopiridol (FP), butyrolactone I (BL) and their derivatives selectively inhibit CDKs and thus constrain tumor cell proliferation under in vitro and/or in vivo conditions. alvocidib 17-29 cyclin dependent kinase 1 Homo sapiens 99-103 10665481-2 1999 Flavopiridol (HMR 1275, L86-8275), a flavonoid derived from an indigenous plant from India, demonstrated potent and specific in vitro inhibition of all cdks tested (cdks 1, 2, 4 and 7) with clear block in cell cycle progression at the G1/S and G2/M boundaries. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 165-183 9427698-1 1998 Flavopiridol (NSC 649890; Behringwerke L86-8275, Marburg, Germany), is a potent inhibitor of cyclin dependent kinases (CDKs) 1, 2, and 4. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 93-136 9802881-2 1998 Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 53-57 9802881-4 1998 Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content. alvocidib 27-39 cyclin dependent kinase 1 Homo sapiens 51-55 9427698-8 1998 While flavopiridol caused cell cycle arrest with decline in CDK1 activity in PC3 cells, apoptosis of SUDHL4 cells occurred without evidence of cell cycle arrest. alvocidib 6-18 cyclin dependent kinase 1 Homo sapiens 60-64 34233076-8 2021 Molecular docking results suggested that compound 3o can interact with the key amino acid residues, E81, L83 and D146, of CDK1 through hydrogen bond just like flavopiridol does. alvocidib 159-171 cyclin dependent kinase 1 Homo sapiens 122-126 21541623-3 1996 As a cytostatic mechanism, however, Flavopiridol strongly inhibits the cyclin-dependent kinases (cdk1, cdk2, cdk4, cdk7), with the potential to cause inhibition of cell cycle progression in G(1) and G(2) by multiple mechanisms relatable to cdk inhibition. alvocidib 36-48 cyclin dependent kinase 1 Homo sapiens 97-101 8895733-1 1996 Flavopiridol (NSC 649890, L86-8275), a potent inhibitor of cyclin-dependent kinase 1/p34cdc2 phosphorylation and kinase activity, is currently undergoing Phase I clinical testing as a potential antineoplastic agent. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 59-84 8895733-1 1996 Flavopiridol (NSC 649890, L86-8275), a potent inhibitor of cyclin-dependent kinase 1/p34cdc2 phosphorylation and kinase activity, is currently undergoing Phase I clinical testing as a potential antineoplastic agent. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 85-92 8674031-1 1996 Flavopiridol (L86-8275), a N-methylpiperidinyl, chlorophenyl flavone, can inhibit cell cycle progression in either G1 or G2 and is a potent cyclin-dependent kinase (CDK) 1 inhibitor. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 140-171 30250647-5 2018 Because flavopiridol is a potent cyclin-dependent kinase (CDK) inhibitor, we found significantly higher CDK1 and CDK2 mRNA expression in three independent cohorts human ACC (p<0.01) and CDK1 protein by immunohistochemistry (p<0.01) in human ACC samples. alvocidib 8-20 cyclin dependent kinase 1 Homo sapiens 104-108 34067359-6 2021 CDK1 selective inhibitor CGP74514A (CGP) and the pan-CDK inhibitor flavopiridol (FLA) arrested OCI-AML3 cells in the G2/M phase, and induced cell apoptosis. alvocidib 67-79 cyclin dependent kinase 1 Homo sapiens 53-56 34067359-6 2021 CDK1 selective inhibitor CGP74514A (CGP) and the pan-CDK inhibitor flavopiridol (FLA) arrested OCI-AML3 cells in the G2/M phase, and induced cell apoptosis. alvocidib 81-84 cyclin dependent kinase 1 Homo sapiens 53-56 30250647-5 2018 Because flavopiridol is a potent cyclin-dependent kinase (CDK) inhibitor, we found significantly higher CDK1 and CDK2 mRNA expression in three independent cohorts human ACC (p<0.01) and CDK1 protein by immunohistochemistry (p<0.01) in human ACC samples. alvocidib 8-20 cyclin dependent kinase 1 Homo sapiens 189-193 21885916-10 2011 Importantly, we found that while both VMY and flavopiridol inhibited intracellular CDK1 catalytic activity, VMY-1-103 was unique in its ability to severely disrupt the mitotic spindle apparatus significantly delaying metaphase and disrupting mitosis. alvocidib 46-58 cyclin dependent kinase 1 Homo sapiens 83-87 28176922-6 2017 Pharmacological inhibition of CDK1/2 by flavopiridol or E2F1 with HLM006474 led to downregulation of Mad2 expression and prevented the increase of Mad2 expression by Skp2. alvocidib 40-52 cyclin dependent kinase 1 Homo sapiens 30-34 27771926-2 2016 Flavopiridol arrests cell cycle progression in the G1 or G2 phase by inhibiting the kinase activities of CDK1, CDK2, CDK4/6, and CDK7. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 105-109 23943501-4 2013 We investigated the effect of a cyclin-dependent kinase (Cdk) inhibitor flavopiridol (FP) that inhibits the action of Cdc2, a key protein in the G2 checkpoint pathway, on TMZ-treated glioma cells. alvocidib 72-84 cyclin dependent kinase 1 Homo sapiens 118-122 23943501-4 2013 We investigated the effect of a cyclin-dependent kinase (Cdk) inhibitor flavopiridol (FP) that inhibits the action of Cdc2, a key protein in the G2 checkpoint pathway, on TMZ-treated glioma cells. alvocidib 86-88 cyclin dependent kinase 1 Homo sapiens 118-122 20419498-3 2011 An extensive dynamic simulation was also performed on a Flavopiridol-CDK1 complex for probing the binding pattern of Flavopiridol in the active site of CDK1. alvocidib 56-68 cyclin dependent kinase 1 Homo sapiens 69-73 20419498-3 2011 An extensive dynamic simulation was also performed on a Flavopiridol-CDK1 complex for probing the binding pattern of Flavopiridol in the active site of CDK1. alvocidib 56-68 cyclin dependent kinase 1 Homo sapiens 152-156 20419498-3 2011 An extensive dynamic simulation was also performed on a Flavopiridol-CDK1 complex for probing the binding pattern of Flavopiridol in the active site of CDK1. alvocidib 117-129 cyclin dependent kinase 1 Homo sapiens 69-73 20419498-3 2011 An extensive dynamic simulation was also performed on a Flavopiridol-CDK1 complex for probing the binding pattern of Flavopiridol in the active site of CDK1. alvocidib 117-129 cyclin dependent kinase 1 Homo sapiens 152-156 21042745-11 2010 Furthermore, sequential treatment with the CDK1-inhibitor, flavopiridol, synergistically enhanced PBOX-induced apoptosis. alvocidib 59-71 cyclin dependent kinase 1 Homo sapiens 43-47 15474478-1 2004 Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). alvocidib 16-28 cyclin dependent kinase 1 Homo sapiens 65-96 20206141-3 2010 Recent data demonstrating enhanced MTA-induced tumour cell apoptosis upon combination with the cyclin dependent kinase (CDK)-1 inhibitor flavopiridol prompted us to examine whether this compound could similarly enhance the effect of the PBOX compounds. alvocidib 137-149 cyclin dependent kinase 1 Homo sapiens 95-126 20206141-6 2010 The addition of flavopiridol following PBOX-6 treatment did however result in an accelerated exit from the G2/M transition accompanied by an enhanced downregulation and deactivation of the CDK1/cyclin B1 complex and an enhanced degradation of the inhibitor of apoptosis protein (IAP) survivin. alvocidib 16-28 cyclin dependent kinase 1 Homo sapiens 189-193 17638911-9 2007 Inhibition of cdc2 activity with flavopiridol decreased survivin expression and sensitized the p21-deficient cells to lexatumumab-induced apoptosis. alvocidib 33-45 cyclin dependent kinase 1 Homo sapiens 14-18 15474478-1 2004 Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). alvocidib 16-28 cyclin dependent kinase 1 Homo sapiens 98-108 15474478-3 2004 The present work describes two molecular models for the binary complexes CDK1:roscovitine and CDK1:flavopiridol. alvocidib 99-111 cyclin dependent kinase 1 Homo sapiens 73-77 15474478-3 2004 The present work describes two molecular models for the binary complexes CDK1:roscovitine and CDK1:flavopiridol. alvocidib 99-111 cyclin dependent kinase 1 Homo sapiens 94-98 15474478-4 2004 These structural models indicate that both inhibitors strongly bind to the ATP-binding pocket of CDK1 and structural comparison of the CDK complexes correlates the structures with differences in inhibition of these CDKs by flavopiridol and roscovitine. alvocidib 223-235 cyclin dependent kinase 1 Homo sapiens 97-101 15474478-4 2004 These structural models indicate that both inhibitors strongly bind to the ATP-binding pocket of CDK1 and structural comparison of the CDK complexes correlates the structures with differences in inhibition of these CDKs by flavopiridol and roscovitine. alvocidib 223-235 cyclin dependent kinase 1 Homo sapiens 215-219 15308730-1 2004 Flavopiridol, roscovitine, and other inhibitors of Cyclin-Dependent Kinases (CDK) inhibit the replication of a variety of viruses in vitro while proving nontoxic in human clinical trials of their effects against cancer. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 77-80 15308730-3 2004 Flavopiridol potently inhibits all tested CDKs and inhibits the transcription of most cellular and viral genes. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 42-46 14751090-3 2004 Flavopiridol exerts multiple effects in tumor cells, including inhibition of multiple CDKs, transcriptional inhibition secondary to disruption of P-TEFb (CDK9/cyclin T), induction of apoptosis, and antiangiogenesis. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 86-90 15217973-1 2004 Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (cdks) to reach clinical trial. alvocidib 0-12 cyclin dependent kinase 1 Homo sapiens 72-76 15217973-9 2004 Inhibition of cyclin B-cdk1 by flavopiridol accelerates exit from an abnormal mitosis associated with taxane-induced cell death and reduces the phosphorylation of survivin, preventing its stabilization and the cellular protection it affords after taxane exposure. alvocidib 31-43 cyclin dependent kinase 1 Homo sapiens 23-27 15023361-4 2004 Rosco preferentially inhibits CDKs involved in cell cycle regulation (CDK1, 2, and 7) or neuronal functions (CDK5), whereas Flavo preferentially inhibits CDKs involved in cell cycle (CDK1, 2, 4, 7) or transcription (CDK7, and 9). alvocidib 124-129 cyclin dependent kinase 1 Homo sapiens 154-158 14519054-1 2003 BACKGROUND: Flavopiridol, a novel flavone derivative, inhibits cyclin-dependent kinase-1. alvocidib 12-24 cyclin dependent kinase 1 Homo sapiens 63-88 14562039-4 2003 In U937 cells, synergistic interactions between MG-132 and flavopiridol were associated with multiple perturbations in expression/activation of signaling- and survival-related proteins, including downregulation of XIAP and Mcl-1, activation of JNK and p34(cdc2), and diminished expression of p21(CIP1). alvocidib 59-71 cyclin dependent kinase 1 Homo sapiens 256-260